Vancomycin Shortage Listing Raises Question On FDA’s Prevention Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA puts antibiotic on its shortage list about five years after American Society of Health-System says problem began; does FDA gets involved in shortage alleviation too late?
You may also be interested in...
Drug Shortage Analysis Puts FDA At Loggerheads With GAO
GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.